Deanne R. Mendoza, TCM’s Executive Vice President of Strategic Partnerships, expresses gratitude for the ongoing support, stating, “This year, TCM is dedicated to exceeding last year’s contributions of 8,282 pounds of pasta and sauce and $10,000 donation. With the participation of thirteen schools and the community, we are striving to make an even more substantial contribution to Caterina’s Club and the communities it serves.”
To further address the issue of food insecurity, TCM has developed a comprehensive Food Insecurity Toolkit for educators, available at www.teachercreatedmaterials.com/foodinsecurity. This resource aims to equip teachers with valuable tools to address and raise awareness about food insecurity among students. TCM will also be giving away 25 copies of the book Lulu and the Hunger Monster™ as part of this year’s initiative to address the broader challenges faced by children in need.
Deanne Mendoza will join a live broadcast on KFI AM 640 on Giving Tuesday, November 28th to encourage widespread participation. During her time on the broadcast, Deanne will highlight total donations from TCM and recognition of the top-performing school and department.
To support this noble cause, visit KFI to find out where you can drop off donations, and visit www.caterinasclub.org for more information. For every dollar donated, a nutritionally balanced meal is available for a child in Orange, Los Angeles, and San Diego counties.
About Teacher Created Materials
Teacher Created Materials develops innovative and imaginative educational materials and services for students worldwide. Everything they do is created by teachers for teachers and students to make teaching more effective and learning more fun. For more information about Teacher Created Materials and their products, visit http://www.tcmpub.com.
Throughout Community Impact Week, Aprio volunteers completed projects at nonprofit organizations in Atlanta, Birmingham, Charlotte, Rockville, and more. With causes ranging from food scarcity to housing support, organizations supported included Bobby Dodd Institute in Atlanta, Community Food Bank of Central Alabama in Birmingham, Red Hook Farms in New York, Families Forward in Charlotte, and Duyan Ni Maria Children’s Home in the Philippines.
“As a non-profit organization, Chattahoochee Nature Center relies on corporate partners like Aprio to support our mission to connect people with nature,” said a spokesperson from Chattahoochee Nature Center. “We are grateful for the Aprio volunteers who worked to restore a critical trail so our 45,000 visiting school children can explore and interpret a new section of woodlands in the Chattahoochee River ecosystem. Thank you for your shared commitment to the environment and education. Together, we can preserve and protect the environment for future generations.”
About Aprio: Aprio is a premier, full-service business advisory and accounting firm that advises clients on achieving what’s next. Aprio professionals work as integrated teams across advisory, audit, tax, outsourcing, talent solutions and private client services, bringing the best thinking and personal commitment to each client. Across practices, Aprio brings together proven expertise, deep understanding and strategic foresight for industries including Manufacturing and Distribution; Non-Profit and Education; Professional Services; Real Estate; Construction; Retail, Franchise and Hospitality; Government Contracting, and Technology and Blockchain. Aprio has grown to over 2,000 team members. To serve clients wherever life or business may take them, Aprio’s teams speak more than 60+ languages and work with clients in over 50 countries. For more, visit http://www.aprio.com/.
Located at 711 E. Chicago Street, the three-story wood frame building integrates a brick and Hardie panel exterior. Units are offered in one bedroom, one bathroom floor plans that allow residents to live independently.
Amenities include a community lounge, computer room, fitness center, laundry facilities, and outdoor space.
Services for residents include case management, life skill training, and employment assistance.
“Hanover Landing is the result of years of advocacy, planning, and collaboration with local agencies and finance partners at the local, regional, county, and state level,” said Jessica Hoff Berzac, Co-Founder and Principal of UPholdings. “The Hanover Township housing task force illuminated a critical need for supportive, service-enriched housing, particularly for individuals with special needs, and Hanover Landing was designed to fill this distinct gap.”
Hanover Township partnered with UPholdings and the Housing Opportunity Development Corporation on this development to meet the high need for service-enriched housing in the area. Ecker Center for Behavioral Health will serve as the lead service provider and operate an on-site clinic.
Brent also gives thanks to Rutemiller’s Army, the group of friends, family members, colleagues and Olympians from the swimming community, who came together to support Brent from diagnosis to partial remission.
“Over the past two years, all my treatments failed to conquer the Multiple Myeloma cancer circulating in my blood. I went through two stem cell transplants, chemotherapy, multiple drug treatments, and cataract, brain, and heart surgery. Along the way, I lost my eyesight, hearing, smell, taste, and feeling in my face, chin, right leg, and toes. But I never lost hope because of the support from the swimming community and Rutemiller’s Army. Now is the time to give back,” said Brent.
Today, Brent has responded well to treatment, surpassing even his doctor’s expectations. He has miraculously recovered and has regained much of his health so that he can swim once again. To mark this occasion, Brent will be swimming in two Arizona pools on November 24-27 and he is encouraging anyone who loves swimming to dive in and join him. He will be joined virtually at other locations by his faithful Rutemiller’s Army, and special guests from his swimming career, including Olympic swimmers Rowdy Gaines, Debbie Meyer, Nathan Adrian, Aaron Peirsol, Elizabeth Beisel, Matt Grevers, Amanda Beard, Roland Schoeman and Darian Townsend. Those who live outside the Arizona-area and want to join in and swim and support Rutemiller’s Army, can swim in their local pool and donate to Rutemiller’s Army.
Brent’s journey to remission is full of many ups and downs, and he has maintained a positive, yet realistic outlook. His story is documented in a self-produced video on swimacrossamerica.org/rutemillersarmy.
“There is no cure for multiple myeloma – there are only treatments,” said Brent. “I am calling on Rutemiller’s Army to swim for a cure.”
Brent is no stranger to the strength of the swimming community. In 1985, he began his association with Swimming World Magazine and he went on to serve as marketing director, publisher, CEO and owner of the magazine. After a 37-year tenure with the publication, he became CEO of the International Swimming Hall of Fame (ISHOF), re-establishing its home in Fort Lauderdale, Florida, and merging the magazine and its multimedia platforms with the Hall. His leadership was integral to the ongoing construction of the Hall’s new facilities, which include the first high-diving tower of its kind in the world. He retired from his magazine and Hall of Fame positions in 2022 after his cancer diagnosis.
In June 2021, Brent discovered what he believed to be a kidney stone causing intense back pain. It was instead a rare bone marrow cancer called plasma cell leukemia or multiple myeloma. He started chemotherapy almost immediately with MD Anderson before being transferred to Mayo Clinic in Phoenix, Arizona.
Then in January 2022, he experienced the first setback by suffering a skin reaction to one of his major medications. Doctors took him off the drug and began discussions for a bone marrow transplant. They were hopeful that a stem cell transplant would help conquer the cancer in his blood. With the cancer growing at an exponential rate, they infused Brent with five million stem cells in March, 2022. Within a month his cancer was under control and in early remission.
However, seven months later in September 2022, his cancer returned. He received radiation for cancer in his jaw and began the process of receiving Chimeric antigen receptor (CAR) T-cell therapy in the form of another bone marrow transplant. CAR T-cell therapy is a way to get immune cells called T cells to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer cells.
While waiting for the new, modified T cells to be transplanted, his cancer was intensifying. He received the CAR-T transplant in October and was briefly released from the hospital, though his marrow was not responding to the treatment. The following month while back in the hospital, he dealt with multiple setbacks including high fevers, poor clotting of wounds, and difficulty walking independently.
Ten days before Christmas, his marrow was still not responding. His wife suggested to his doctors to give Brent a stem cell boost with the five million of his stem cells that were still banked in cold storage. After the boost of three million stem cells, his initial tests showed no signs of cancer and he was released on December 28 – the day of his 37th wedding anniversary.
“I couldn’t wait to get home, hold my grandsons, get back in shape, and dive into the pool as soon as I felt strong enough,” said Brent.
In February 2023, Brent received test results from his doctors showing signs that the cancer was undetectable.
“They said I had the cleanest bone marrow they’d ever seen!” shared Brent. “We still needed to wait and let the cells do their job but that was fantastic news.”
Then in March, Brent fought another setback as he received the news that his cancer had returned again, and this time, in the form of a brain tumor. Doctors acted quickly and removed the tumor, leaving a large U-shaped scar on the back of his head.
He then learned that cancer had attacked his heart and a new brain tumor formed after the surgery. Brent received radiation treatments for the brain tumor and a pacemaker in his heart to combat the new diagnoses.
After treatment, Brent was feeling well enough to resume hiking and work on regaining his strength, even though the cancer was still growing in his blood.
“Then everything changed. In late 2022, the FDA had granted emergency approval for a new drug called Teclistamab for the treatment of adult patients with relapsed or refractory multiple myeloma,” said Brent. “I was lucky to have my doctors know this and I underwent treatment in May 2023. It was my last hope.”
After a 15-day treatment plan was implemented, Brent was feeling hopeful and healthy. His tests revealed that cancer levels in his blood were below normal and his brain tumor resolved. Brent was optimistic and slowly healing. In July 2023, Brent was in a state of “Very Good Partial Remission” and remains in that state today.
“Before that emergency FDA approval, we didn’t know what our next steps were. And to be honest, we still don’t know what will happen from here. But we’re hopeful and grateful, and I want Rutemiller’s Army to be my legacy and continue to fight towards a cure.”
Funds raised by Brent and Rutemiller’s Army will fund a cancer research project guided by the Swim Across America Research and Grants Committee.
Swim Across America was founded in 1987 with its first open water event in Long Island Sound. Since that time, the nonprofit organization has raised more than $100 million to fight cancer. In its 36 years of “making waves to fight cancer,” more than 100,000 swimmers and 150 Olympians have swum the circumference of the earth three times, uniting a movement to fight cancer that has created a groundswell of support spanning all generations. Today, more than 24 communities hold open water swims and charity pool swims each year, from Nantucket to under the Golden Gate Bridge, which support innovative cancer research, detection and patient programs.
Swim Across America’s funding of clinical trials for patients helped contribute to four FDA approved life-saving immunotherapy cancer treatments: Yervoy, Opdivo, Tecentriq and Keytruda. In June of last year, a clinical trial at Memorial Sloan Kettering was published in The New England Journal of Medicine that showed a 100 percent success rate in treating patients in a phase 2 clinical trial for advanced rectal cancer with dostarlimab, an immunotherapy treatment produced by GlaxoSmithKline. The clinical trial at Memorial Sloan Kettering was funded by early-stage grant funding from Swim Across America. More than 60 scientific grants are funded each year and there are now ten dedicated Swim Across America Labs at major institutions including: Children’s Healthcare of Atlanta, John Hopkins Medicine Baltimore, Rush University Medical Center Chicago, Baylor Scott & White Charles A. Sammons Cancer Center in Dallas, Memorial Sloan Kettering Cancer Center New York, Infusion Center at Nantucket Cottage Hospital, UCSF Benioff Children’s Hospital Oakland and San Francisco, the Seattle Cancer Care Alliance, The Swim Across America Pediatric Research Lab at Columbia University Medical Center New York, and at Meyer Cancer Center at Weill Cornell Medicine.
Swim Across America, Inc. (SAA) is dedicated to raising money and awareness for cancer research, prevention and treatment through swimming-related events. With the help of hundreds of volunteers nationwide and past and current Olympians, Swim Across America is helping find a cure for cancer through athleticism, community outreach and direct service. To learn more visitswimacrossamerica.org or follow on Facebook @SwimAcrossAmerica or on Instagram or Twitter @SAASwim.
Dr. Cunniffe, the lead author of the study, emphasized the importance of their findings, stating, “This study provides an update on state-of-the-art air cleaning technology to equip doctors to advise their patients effectively. HEPA filters were identified as the most efficient in removing airborne particles, including allergens and fine particulate matter. Furthermore, our research highlighted the remarkable effectiveness of activated carbon filters in eliminating volatile organic compounds (VOCs) and odors, while UV-based technology was found to be a valuable addition to filtered HVAC systems.”
The study’s recognition by ACAAI as part of their press kit underscores its significance in the field of allergology, asthma, and immunology. The iAIR Institute is proud to have its work highlighted at this prestigious event, emphasizing the Institute’s commitment to advancing and disseminating research, improving public policy and promoting the importance of healthier indoor environments for all.
The iAIR Institute’s research garnered significant interest and acclaim at the ACAAI Annual Scientific Meeting 2023. Attendees expressed enthusiasm for the study’s potential to enhance the medical community’s understanding of IAQ and provide valuable guidance for their patients.
Dr. John McKeon, CEO and Principal of the iAIR Institute, commented, “Our participation in the ACAAI Annual Scientific Meeting reaffirms our dedication to improving indoor air quality and supporting the healthcare community in their efforts to provide expert advice to patients. We encourage healthcare professionals to consider third-party tested air cleaning devices that are performance validated and, ideally, certified to relevant standards.”
The field of air cleaning technology is experiencing huge growth and evolving rapidly with research developments. Approaches such as electrostatic precipitation, photocatalytic oxidation and plasma-based air cleaning all demonstrate huge potential and are likely to positively impact IAQ across both residential and shared buildings in the future. The iAIR Institute looks forward to continued collaboration with fellow experts and researchers in the field of indoor air quality and remains dedicated to improving IAQ for the benefit of public health.
For more information about the study and the iAIR Institute’s contributions to IAQ research, please visit https://iair.institute.
About iAIR Institute
The iAIR Institute is a leading institution committed to advancing knowledge in the field of indoor air quality (IAQ). Through strategic partnerships and ground-breaking research initiatives, the Institute addresses crucial aspects such as consumer practices, labelling, product development, and the design of the built environment. Advocating for policy changes and empowering innovators with technical solutions, the iAIR Institute strives to enhance indoor air quality on a global scale.
The HITRUST risk-based, two-year certified status, initially awarded to the organization in September of 2022, confirmed Chapters Health’s hospice platforms met key regulations and industry-defined requirements and appropriately manage risk. The achievement elevated Chapters Health into exclusive group of organizations worldwide that have earned this certification. By including federal and state regulations, standards and frameworks, and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protections challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.
“The HITRUST Assurance Program is rigorous and reliable because of the comprehensiveness of control requirements, depth of review, and consistency of oversight” said Bimal Sheth, executive vice president, standards development & assurance operations, HITRUST. “HITRUST Risk-based, 2-year (r2) Certification demonstrates Chapters Health System is taking the most proactive approach to cybersecurity, data protection, and risk management.”
“HITRUST awarding the certification to Chapters Health for another year is the result of the collaboration and hard work from many teams in this organization,” said Mike Parkin, director, IT security CISO, Chapters Health System. “It validates the efforts put in to manage risks, improve security posture and meet requirements within the CareCentrium Environment residing at the Flexential datacenter in Tampa.”
About Chapters Health System As a progressive leader and premier healthcare organization, Chapters Health System is dedicated to delivering innovative care throughout chronic illness progression and beyond. Since 1983 as a community-based, not-for-profit organization, Chapters Health has provided choices, education and guidance through its managed affiliates. All offerings are provided to improve the patient/family experience well in advance of end-of-life needs. In 2023, Chapters Health was named a Top Workplaces USA award-winner; in 2022, earned certified status for information security from HITRUST and for the sixth consecutive year was recognized as a great workplace in the Aging Services category by the independent analysts at the Great Place to Work® Institute. To learn more, visit http://www.chaptershealth.org, like us on Facebook or follow us on X and LinkedIn.
FreeOx Biotech lead asset recommended by NIH/NINDS SPAN network for further development. FreeOx Biotech Adds Leadership for Advancing Ox-01 to Phase III and Commercialization
BARCELONA, Spain, Nov. 16, 2023 /PRNewswire-PRWeb/ — FreeOx Biotech SL, a late-stage clinical biopharmaceutical company pioneering the development of a novel drug class for Acute Ischemic Stroke (AIS), announced today that the National Institutes of Health, NINDS’ SPAN (Stroke Preclinical Assessment Network), endorsed Uric Acid (the active ingredient of Ox-01, the company’s Phase III-ready investigational drug) as the only one of five interventional drug candidates for which data supported further clinical evaluation. As reported in SCIENCE TRANSLATIONAL MEDICINE, FreeOx’s lead asset – was shown to be an effective emergency adjunct therapy to Mechanical Thrombectomy (MT) for the treatment of AIS, demonstrating unprecedented efficacy compared to five other candidate interventions. As such, the NINDS also indicated potential interest in funding Ox-01’s Phase III trial. The company has strong intellectual property covering Uric Acid and its use in stroke treatment.
“The NINDS’ endorsement underscores their confidence in the efficacy and potential of Ox-01 as a ground-breaking therapy for acute ischemic stroke. On top of our compelling Phase II data, the Phase III trial, once successfully completed, will pave the way for the marketing authorization of Ox-01 in the U.S. and EU, as an adjunct therapy to mechanical thrombectomy. We are confident that once approved, Ox-01 will significantly reduce disability in AIS patients,” noted Emmett-Phil Coriat, FreeOx Chairman and Chief Executive Officer.
FreeOx also announced today the addition of key personnel to the company’s leadership and advisory teams, including a new Chairman of the Board and Chief Executive Officer; a newly appointed Board Director; and a Strategic Development Advisory Board to lead the company through its upcoming pivotal Phase III clinical program and subsequent commercial registration and marketing activities. Carlos Lurigados, FreeOx’s co-founder and former CEO, has assumed both the Chief Operating and Chief Financial Officer roles.
New Chairman of the Board and Chief Executive Officer: Emmett-Phil Coriat
“FreeOx is uniquely positioned to lead the field of cerebroprotective therapies. Its lead asset has been observed to reperfuse brain vasculature during a stroke as well as to protect the penumbra. The company’s founders pioneered the strategy of administering Uric Acid to restore microcirculation to oxygen-deprived brain cells and were recently recognized by the U.S. National Institutes of Health SPAN program for their breakthrough work. I believe FreeOx will be the first commercial adjunct therapy to address the significant unmet needs and raise the standard of care in stroke. As both Chairman of the Board and CEO, I look forward to the opportunity to collaborate with the company’s leadership and advisors to advance this work first in stroke and later, to even broader neurological indications,” said Emmett-Phil Coriat, newly appointed FreeOx Board Chair and CEO.
Emmett brings to FreeOx more than 25 years of experience in biotech/medtech as a venture capitalist, founder, and CEO of startups, with a successful track record in dealmaking and exits. He has held diverse roles and advisory positions in Canada, the U.S., Israel, and the U.K. As a partner, he led the creation of the Biotech/Medtech transactional advisory practice and co-founded the Boston office for AEC Partners, a strategy and transactional advisory boutique in life sciences. Emmett was previously a partner at T2C2 Capital, a VC fund behind companies such as Enobia Pharma. His accomplishments include successfully innovating with endogenous products, including an asset sale to Eli Lilly in 2015. Emmett holds an MBA from the London Business School (UK), a Pharmacy degree from University of Montreal and a diploma in Intellectual Property Management from McGill University. Emmett is also certified as a Forest Therapy guide, and co-founded PaRx Canada, which has grown to become one of the world’s largest physician-prescribed ecotherapy programs. He began his career at L’Oréal and holds dual Canadian-Spanish citizenship.
New Board Member: Laurent van Lerberghe
Laurent van Lerberghe brings to the FreeOx Board of Directors a wealth of experience, spanning over 25 years in operational and strategic leadership across pharma businesses. He has a strong track record of leading and developing businesses globally. Over the last three years, he served as Chief Strategy Officer at Sanofi, working closely with the CEO and contributing significantly to the company’s growth as one of the architects of multiple strategic acquisitions. He also expedited funding in oncology, genomic medicines, and digital health. Before Sanofi, Laurent held various high-level commercial positions at Abbott for a decade in the US, Europe, and Asia. Laurent’s strategic insights and track record bringing science to patients will play an important role as we continue to develop and partner Ox-01. Laurent is now an entrepreneur investor, focusing on accelerating digital health across Europe, with neurology being one key area.
“FreeOx is well positioned for success, not only in Phase III but also in the field of cerebroprotective therapy where there has been almost no innovation since the approval of Mechanical Thrombectomy. Despite the fact that MT has improved outcomes for stroke patients, there are a significant number of stroke survivors left unable to live independently post-stroke. As such, they ravage healthcare resources, not to mention present often insurmountable challenges to patients and families alike. It is this gap that I believe FreeOx will address with an emergency adjunct AIS treatment that restores brain microcirculation, and thereby raises standard of care worldwide,” added van Lerberghe.
New Development & Strategic Advisory Board (DSAB)
Coriat said that FreeOx has created a new Development and Strategic Advisory Board to support management’s planning for its pivotal trial, Ox-01’s registration, commercialization and market access. He also expects the DSAB to assist in identifying future pipeline opportunities based on FreeOx’s proprietary liposomal formulation platform, including UA and other neurology indications. Appointed to Chair the DSAB is Joan Bigorra, MD, former General Manager of Novartis Pharma Spain. Dr. Bigorra sat on Novartis Pharma’s International Innovation Board and set up programs focused on Market Access Strategy and Structure. Prior to Novartis. he was Medical Director, and Head of R&D for Bayer Healthcare and Boehringer Ingelheim. Angel Chamorro, M.D, FreeOx co-founder and senior scientific advisor will co-chair the DSAB while Tudor G. Jovin, the company’s co-founder and senior medical advisor has agreed to be its first independent member. Tudor is an esteemed expert specializing in both interventional and non-interventional treatments for stroke and cerebrovascular disorders, with over 300 influential publications.
For more information about FreeOx Biotech and its groundbreaking stroke treatment technology, please visit the company’s website at https://freeoxbiotech.com/.
About FreeOx Biotech
FreeOx Biotech is a leading late-stage clinical-stage biopharmaceutical company dedicated to developing Cerebrovascular Protective Therapy, a new drug class for the emergency treatment of Acute Ischemic Stroke (AIS) patients. By focusing on restoring microcirculation homeostasis and enhancing penumbra reperfusion, FreeOx Biotech aims to revolutionize stroke care and improve patient outcomes. FreeOx’ s lead product, Ox-01, is Phase III- ready. FreeOx is building a pipeline based on a proprietary liposomal formulation technology that broadly expands opportunities in neurology. Founded by Dr. Ángel Chamorro, a leading stroke neurologist and pioneer in the use of Uric Acid as an emergency treatment for AIS, FreeOx ‘s novel adjunct drug has been shown to reperfuse the brain microcirculation. By contrast, current emergency AIS treatments are effective only in addressing recanalization (macrocirculation restoration).
Dami Osunsanya and Tess Posner Join AI4ALL Board of Directors, Additional Funds Power Nonprofit’s Efforts to Make Professional Roles in AI More Accessible to Historically Excluded Talent
SAN FRANCISCO, Nov. 16, 2023 /PRNewswire-PRWeb/ — AI4ALL, a national nonprofit that is transforming the pipeline of AI practitioners and creating a more inclusive, human-centered discipline, announced it has appointed Dami Osunsanya and Tess Posner to the Board of Directors. Both will support and advise the organization as it continues to build corporate and academic partnerships, as well as mentorship and training programs that will empower the next generation of AI professionals. Additionally, AI4ALL has secured new and follow-on funding from major corporations that will support its mission. New funding comes from Atlassian and Alan Eustace, and renewal funding comes from General Motors, Nielsen, Motorola Solutions Foundation, and Capital One. Renewed, previously committed funding for the calendar year comes from SoftBank, Pivotal Ventures, Reboot Representation and AIM-AHEAD. This funding and support that AI4ALL’s sponsors provide is critical to support the organization’s mission of establishing the next generation of AI Changemakers that humanity needs by equipping diverse, emerging talent with the responsible AI skills and social capital needed for collective success.
“Dami and Tess make outstanding additions to the Board of Directors,” said Emily Reid, CEO of AI4ALL. “We have relied on their guidance and leadership for a number of years with Dami as an Advisor and Tess as founding CEO. They join an impressive group of board members who are passionate about and integral to the changes we want to see in the AI field.”
Reid continued: “We are enormously grateful for grants and other financial support provided by organizations that are creating the future of technology. They all understand the importance of fostering the next generation of talent – especially in AI – and our work would not be possible without them.”
Osunsanya, who has served as an advisor to AI4ALL for more than two years, is partner, co-head of the Open Opportunity Fund founded by SoftBank Group, where she launched and manages a $100M-plus early stage and growth stage vehicle for tech enabled companies in the U.S. The Fund has invested in over 80 tech companies since 2020.
Osunsanya also serves on the Boards of Welcome Tech and Heru, and on the Operators Council Board of f7 Ventures. Prior to her role with the Open Opportunity Fund founded by SoftBank Group, Osunsanya was an investment director at SoftBank Investment Advisers, and held roles in corporate finance and strategy with Intel Corporation, The Kraft Heinz Company and Sprint. Osunsanya holds an MBA from The University of Chicago Booth School of Business, and a bachelor of business administration, Finance, Chinese from Emory University – Goizueta Business School.
Posner is an award-winning social entrepreneur and musician focused on inclusion, equity and empowerment. She served as founding CEO of AI4ALL from 2017 through 2021, and grew it to over 20 AI education partner sites and to become an award-winning and internationally recognized organization. Prior to AI4ALL, she was managing director of TechHire at Opportunity@Work, a national initiative launched out of the White House to increase diversity in the tech economy. Prior to that, Posner built and led Samaschool, an educational initiative to build technical skills and confidence for the future of work that she scaled across the U.S. and internationally.
Posner’s social impact work has earned recognition including her selection as the winner of the VentureBeat Women in AI Award and one of the 100 Brilliant Women in AI Ethics in 2020. A co-author of “The People Centered Economy: The New Ecosystem For Work,” Posner has been featured by numerous media outlets, including Wall Street Journal, CNBC, Entrepreneur, Fast Company and more. Her work has been funded by top national foundations and influencers including Melinda Gates, Jensen Huang, Google.org, Microsoft, Capital One Foundation, JPMorgan Chase Foundation, Autodesk and the Robin Hood Foundation. She holds a master’s degree from Columbia University and a bachelor’s in liberal arts from St. John’s College.
AI4ALL empowers students to be AI Changemakers by cultivating an environment where they develop skills in critical thinking and relationship-building, and expertise in responsible AI. AI4ALL champions the diverse next generation of AI changemakers through education, ethics, and relationship-driven networks. The organization focuses specifically on serving Black, Hispanic and Latinx, and Indigenous students; and women and non-binary students.
AI4ALL is a national nonprofit that is transforming the pipeline of AI practitioners and creating a more inclusive, human-centered discipline. They are establishing the next generation of AI Changemakers that humanity needs by equipping diverse, emerging talent with the responsible AI skills and social capital needed for collective success. AI4ALL has received funding from Melinda Gates/Pivotal Ventures, Prudential Financial, General Motors, Nielsen, and SoftBank among others and has been featured in the New York Times, TIME, CNN, The Washington Post, USA Today, The Atlantic and the Today Show.
Trailblazing female leaders share their journeys and the importance of women having seats in the boardroom and throughout a company’s organizational chart
NEW YORK, Nov. 16, 2023 /PRNewswire-PRWeb/ — The Women’s Lunch returns to Manifest Vegas this February to celebrate women in the supply chain in partnership with DHL Supply Chain, FlavorCloud, Food Logistics, and Supply & Demand Chain Executive on February 7th, 2024, at Caesars Forum. Manifest Vegas is the only event that brings together industry executives, top venture investors, cutting edge startups and technology leaders that strive to find solutions to critical end-to-end supply chain and logistics disruptions – while identifying breakthrough technologies.
Gartner research shows that women have made a strong comeback to the supply chain workforce in 2023, with gains at nearly every level of leadership. The advances were particularly prominent at the C-Suite and executive level, where 26% of those roles (CSCO, SVP, EVP, CPO) are now filled by women, an all-time high and up from 19% in 2022. This is a promising trend as several reports show that a woman in a senior-most role leads to more women in leadership and all roles within the organization.
The Women’s Lunch will welcome Lindsay Kaplan, who is the Co-Founder of Chief, a private membership created to connect and support women executives, that was recently named to TIME’s 100 Most Influential Companies. Lindsay has been recognized as one of Business Insider’s Most Innovative CMOs in the World and one of Ad Age’s Leading Women. Also joining the stage is the CEO & Founder of FlavorCloud, Rathna Sharad. She founded this enterprise ecommerce SaaS solution in 2018 when she realized that “anywhere to anywhere” logistics became a critical need in the industry. Sharad was recently a Forbes #Next1000 honoree as well as Inc 5000 20 Most Inspiring Entrepreneurs of 2022.
Lindsay and Rathna will both share their inspiring stories and discuss the importance of diversity in supply chain organizations and what they have learned talking to leaders of some of the largest companies in the world.
“I am honored to keynote the Women’s Lunch at this year’s Manifest Vegas conference alongside Rathna and in the company of so many accomplished and inspiring industry executives. I look forward to discussing the promising strides women have made in the supply chain workforce, how the industry can continue to advance and retain these leaders, and why building a diverse workforce is so critical to its success” said Lindsay Kaplan.
Manifest Vegas’ commitment to diversity doesn’t end with the Women’s Lunch. The importance of including different perspectives from the supply chain and logistics community can be seen throughout the entire Manifest Vegas speaker line-up which can be viewed on the website.
While it is called a Women’s Lunch, both women and the men who support them are invited to attend.
Manifest is the largest and only event for Industry Leaders, Innovators and Investors attracting Startups, 3PLs, Forwarders, Retailers, CPGs, Distributors, Manufacturers, Ports and Rails to uncover the newest technologies, innovations and partnerships that are transforming the way goods move globally. Our next event is scheduled for February 5th – 7th, 2024, at Caesars Forum, Las Vegas.
Manifest is powered by Connectiv, the premiere events studio that produces Blueprint and Medicarians.
ReferralMD’s new Consult Management features and expanded partnership with ConferMED strengthen eConsults, enhancing patient care and cost savings.
MT. PLEASANT, S.C., Nov. 16, 2023 /PRNewswire-PRWeb/ — ReferralMD, the leader in care coordination and patient access technology, announces the release of its new Consult Management features and the extension of its partnership with ConferMED. With eConsults, ReferralMD improves the patient experience, reduces costs, and expands the scope of primary care by providing crucial clinical guidance from specialists.
Primary care providers can confer with specialists through eConsults before making referrals for face-to-face care. Organizations can send consult requests to specialists in their internal network and in the ConferMED virtual network, ensuring that eConsults are reviewed promptly.
The key enhancements in the Consult Management solution include:
Structured Workflow with Customization
Automated Alerts Similar to Referrals
Access to ConferMED Virtual Specialist Network
Customizing In-Network Specialist Availability
Converting Consults to Referrals
New Consult Management Reports
“By extending the care coordination capabilities in our platform, providers can seamlessly incorporate eConsults and Referrals into their workflow through a tight integration with their EHRs,” stated Rick Hammer, Chief Product Officer at ReferralMD. “We are also deepening our collaboration with ConferMED to give our customers access to ConferMED’s impressive network of specialists focused on eConsults.”
Daren Anderson, MD, President of ConferMED, states, “Referrals from primary care to specialists are a pain point for practices and patients. Our partnership with ReferralMD offers a complete end-to-end solution to help primary care providers meet as many of their patient’s needs as possible in their clinics while efficiently managing the process of referring to outside specialists whenever needed.”
With these new Consult Management features, ReferralMD continues to demonstrate its commitment to advancing healthcare technology and providing innovative solutions that revolutionize how primary and specialty care providers collaborate.
About ReferralMD
ReferralMD delivers proven consult and referral management, patient access, and CRM marketing solutions that empower hospitals, health systems, networks, and payers to streamline the referral process, decrease patient leakage, and improve communication between providers and patients. With powerful clinical decision support tools and real-time analytics, ReferralMD helps healthcare providers increase revenue, drive operational efficiencies, and improve customer service. To learn more about ReferralMD, please visit https://getreferralmd.com.
About ConferMED
ConferMED allows primary care providers to quickly and easily communicate with a national network of specialists in all major adult and pediatric medical and behavioral health disciplines via a secure, HIPAA-compliant platform. Questions requiring a specialty consult frequently can be resolved for the PCP without requiring the patient to incur the cost and inconvenience of a specialist visit. ConferMED is currently providing eConsults to primary care providers and practices in 30 states. To learn more, visit http://www.ConferMED.com.
